摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl-methyl-{3-[3-(4-methyl-piperidin-1-yl)-4-nitro-phenyl]-prop-2-ynyl}-amine | 954424-88-5

中文名称
——
中文别名
——
英文名称
ethyl-methyl-{3-[3-(4-methyl-piperidin-1-yl)-4-nitro-phenyl]-prop-2-ynyl}-amine
英文别名
N-ethyl-N-methyl-3-[3-(4-methylpiperidin-1-yl)-4-nitrophenyl]prop-2-yn-1-amine
ethyl-methyl-{3-[3-(4-methyl-piperidin-1-yl)-4-nitro-phenyl]-prop-2-ynyl}-amine化学式
CAS
954424-88-5
化学式
C18H25N3O2
mdl
——
分子量
315.415
InChiKey
MYVXKDKZTBCRIQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    23
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    52.3
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    N-乙基甲基胺二氯甲烷 为溶剂, 反应 0.33h, 以100%的产率得到ethyl-methyl-{3-[3-(4-methyl-piperidin-1-yl)-4-nitro-phenyl]-prop-2-ynyl}-amine
    参考文献:
    名称:
    INHIBITORS OF C-FMS KINASE
    摘要:
    该发明涉及以下式I的化合物:其中Z、X、J、R2和W如规范中所述,以及其溶剂合物、水合物、互变异构体和药用可接受的盐,这些化合物抑制蛋白酪氨酸激酶,特别是c-fms激酶。提供了治疗自身免疫疾病的方法;以及具有炎症成分的疾病;治疗卵巢癌、子宫癌、乳腺癌、结肠癌、胃癌、毛细胞白血病和非小细胞肺癌的转移;以及治疗疼痛,包括肿瘤转移或骨关节炎引起的骨骼疼痛,或内脏、炎症和神经源性疼痛;以及骨质疏松症、Paget病和其他骨吸收导致发病率的疾病,包括关节炎、假体失败、破骨性肉瘤、骨髓瘤和肿瘤转移至骨骼的方法,使用式I的化合物也提供了。
    公开号:
    US20070249649A1
点击查看最新优质反应信息

文献信息

  • Inhibitors of C-FMS kinase
    申请人:Illig Carl R.
    公开号:US08674100B2
    公开(公告)日:2014-03-18
    The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are as set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. The compounds of formula I are useful for treating a variety of disorders including autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and psoriasis.
    本发明涉及I式化合物:其中Z,X,J,R2和W如规范所述,以及其溶剂化物,水合物,互变异构体和药学上可接受的盐,该化合物抑制蛋白酪氨酸激酶,特别是c-fms激酶。I式化合物对于治疗多种疾病包括自身免疫性疾病如类风湿性关节炎,多发性硬化症和牛皮癣等非常有用。
  • Inhibitors of c-fms kinase
    申请人:Janssen Pharmaceutica NV
    公开号:US09221797B2
    公开(公告)日:2015-12-29
    The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
    本发明涉及式I的化合物:其中Z、X、J、R2和W在规范中说明,以及其溶剂化物、水合物、互变异构体和药学上可接受的盐,该化合物抑制蛋白酪氨酸激酶,特别是c-fms激酶。本发明还提供了使用式I的化合物治疗自身免疫性疾病和具有炎症成分的疾病;治疗卵巢癌、子宫癌、乳腺癌、结肠癌、胃癌、毛细胞白血病和非小细胞肺癌的转移;以及治疗疼痛,包括肿瘤转移或骨关节炎引起的骨骼疼痛,或者内脏、炎症和神经源性疼痛;以及骨质疏松症、帕吉特病和其他骨吸收介导的疾病,包括关节炎、假体失效、骨溶性肉瘤、骨髓瘤和转移至骨骼的肿瘤。
  • Inhibitors of C-FMS Kinase
    申请人:Janssen Pharmaceutica N.V.
    公开号:EP2687516A1
    公开(公告)日:2014-01-22
    The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
    本发明涉及式 I 的化合物: 其中Z、X、J、R2和W如说明书所述,以及它们的溶解物、水合物、同系物和药学上可接受的盐,可抑制蛋白酪氨酸激酶,特别是c-fms激酶。治疗自身免疫性疾病的方法;治疗具有炎症成分的疾病的方法;治疗卵巢癌、子宫癌、乳腺癌、结肠癌、胃癌、毛细胞白血病和非小肺癌转移的方法;治疗疼痛的方法,包括由肿瘤转移或骨关节炎引起的骨骼疼痛,或内脏疼痛、炎症疼痛和神经源性疼痛;以及骨质疏松症、Paget 病和其他骨吸收介导发病的疾病,包括关节炎、假体失效、溶骨性肉瘤、骨髓瘤和肿瘤向骨骼转移,也提供了式 I 化合物。
  • US8674100B2
    申请人:——
    公开号:US8674100B2
    公开(公告)日:2014-03-18
  • US9221797B2
    申请人:——
    公开号:US9221797B2
    公开(公告)日:2015-12-29
查看更多